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Background: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders with different disease
manifestations among various populations. There are few reports of JIA among indigenous Africans especially sub-
Saharan Africa. We present herein the clinical patterns of JIA encountered at a tertiary hospital in Lusaka, Zambia.
Method: Hospital records of patients with a diagnosis of chronic arthritis with onset at the age of 16 years or less
presenting to University Teaching Hospital, Lusaka, Zambia for the periods 1994–98 and 2006–2010 were
retrospectively reviewed and reclassified as Juvenile Idiopathic Arthritis (JIA) based on the International League of
Associations for Rheumatology (ILA R) JIA diagnostic criteria.
Results: In total, 126 patients with chronic arthritis of onset at age 16 years or less were evaluated over these
periods at the hospital. Of these, 85 could further be analyzed by ILAR JIA criteria but 7 (8.24%) were HIV
seropositive and were assessed separately. The average age at disease onset among the 78 JIA patients was
8.70 years (range: 1–15 years) with average age at first visit to hospital being 11.3 years (range: 2 to 25 years) and
with a female to male ratio of 1.2:1. Polyarticular rheumatoid factor negative JIA, at 34.62%, was the most frequent
type of chronic arthritis encountered. Oligoarthritis was found in 32.05% while 11.54% and 14.10% were
polyarticular rheumatoid factor positive and systemic JIA, respectively. Enthesitis-related arthritis was found in 6.41%
and only 1.28% were determined to have psoriatic arthritis among this population.
Conclusion: JIA is predominantly a polyarticular rheumatoid factor negative disease in Zambia. Late presentation is
an issue with major implications for educational input and resource acquisition. There is need to elucidate the
genetics and environmental factors of JIA in this region.
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Juvenile Idiopathic Arthritis (JIA) is now known not to
be a single disease entity but a heterogeneous group of
chronic arthritic disorders of unknown cause in children.
Characteristic of these disorders are their onset before
the age of 16 years and duration of at least 6 weeks [1].
Reports on the prevalence and incidence of JIA suggest
variability among different ethnic and geographically dis-
tinct populations [2-5]. Although there are reports from
several regions of sub-Saharan Africa, there remains a* Correspondence: Jameschipeta@smuth-mru
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reproduction in any medium, provided the orsignificant information gap [6-9]. In this paper, we de-
tail the spectrum and epidemiological subtypes of JIA
among indigenous black Zambian children seen at a
tertiary level hospital. Diagnostic and classification dif-
ficulties engendered by limited diagnostic procedures,
late presentation to hospital and irregular follow up are
highlighted.Methods
The records of patients with a diagnosis of arthritis of
six weeks or more and of onset at the age of 16 years or
less, presenting to University Teaching Hospital (UTH),
Lusaka, Zambia during the periods 1994–98 and 2006–
2010 were reviewed. UTH is a 1,800-bed tertiary care
hospital with a 415-bed Paediatrics and Child Health
wing (355 general pediatrics beds and 60 neonatal cots/l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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out-patient rheumatology clinics at the University Tea-
ching Hospital [UTH] in Lusaka, Zambia from two dis-
tinct time periods; a 5-year period from January 1994 to
December 1998; a 4-year period from 2006 to 2010. Pa-
tients attended these clinics by referral from host hos-
pital doctors for diagnostic evaluation or second opinion
on cases that had presented diagnostic difficulties. The
patients had been referred by their primary care health
facilities within Lusaka and from other parts of Zambia.
During 1994–98 patients were evaluated prospectively
by PN in an adult rheumatology clinic setting, and by JC
from 2006 – 2010 in a new paediatric rheumatology
clinic. During the period 2006–2010 we used the ILAR
classification [10]. For the period 1994–98 the European
Union League of Associations for Rheumatology (EULAR)
system was used to classify patients into onset sub-
types as follows:
1. Pauciarticular onset (four or fewer joints involved)
2. Polyarticular onset (five or more joints affected)
3. Systemic onset (arthritis associated with spiking
fever for at least 2 weeks with or without a
typical rash).
This retrospective review of case records involved re-
classifying each of the patients by the ILAR diagnostic
JIA criteria and then compiling respective clinical data
of each patient. Clinical, haematological, immunological,
radiological and other relevant findings from the history
were obtained from the available records for the review.
Anti-nuclear antibody (ANA) tests were not routinely
available during either study period and hence it was not
part of the analysis. Thus reclassification of each patient
into the ILAR subsets was based on the presence of
rheumatoid factor, enthesitis and the natural history of
the articular disease. Patients were thus re categorized as
systemic arthritis, oligoarthritis, polyarthritis (RF ne-








Overall 78(100%) 1.2:1 8.7
Systemic JIA 11(14.1%) 1:1.2 6
Polyarticular RF̄(−) JIA 27(34.6%) 1.7:1 10.
Polyarticular RF̄(+) JIA 9(11.5%) 9:0 11
Oligoarticular arthritis 25(32.0%) 1:1.1 6.
Psoriatic arthritis JIA 1(1.3%) NA
Enthesitis related arthritis 5(6.4%) 1:4 10
Others (undifferentiated) 0(0%) NA
NB.: JIA Juvenile Idiopathic Arthritis, STD Standard Deviation, RF (−) Rheumatoid Facenthesitis related arthritis (ERA) and others (or undiffer-
entiated). Extended and persistent oligoarthritis ILAR
subtypes depend on a period of observation which for
many of our patients was not possible due to the retro-
spective nature of the study, the delay in presentation
and the high rates of loss to follow up. Hence in this re-
view we did not sub-classify oligoarthritis into persistent
and extended oligoarthritis. Patients who had signs and
symptoms of other arthritis such as acute rheumatic
fever, septic arthritis, systemic inflammatory disorders
(systemic lupus erythematosus, vasculitis, or dermato-
myositis), malignancy, human immune deficiency virus
type 1 (HIV-1) infection, or metabolic diseases were
excluded from the study after careful scrutiny of the re-
spective case records. This study formed part of a gen-
eral clinical audit of the UTH pediatric rheumatology/
immunology clinic of the study period and was approved
by the local ethics committee, the University of Zambia
School of Medicine Biomedical Research Ethics Com-
mittee (UNZABREC).
Results
Prevalence of JIA subtypes
The JIA subgroup data are shown in Table 1. In total,
126 patients with chronic arthritis of onset at the age of
16 years or younger were seen at UTH. Eight-five of
these could further be analyzed by the ILAR JIA criteria.
7 (8.24%) were HIV infected and were excluded from
the analysis. The 78 JIA patients comprised 43 girls and
35 boys giving a female to male ratio of 1.2:1. The over-
all average age at disease onset was 8.7 years (range:
1–15 years) and the majority of the patients presented
late with average age at first visit to hospital being
11.3 years (range: 2 to 25 years). Polyarticular rheuma-
toid factor negative JIA , at 34.6%, was the most frequent
type. Oligoarthritis was found in 32.1% while 11.5% and
14.1% were polyarticular rheumatoid factor positive and
systemic JIA, respectively. Enthesitis-related arthritis was












0±5.00 1–15 11.3±5.8 2–25
±4.3 2–15 8±4.00 4.5–18
70±3.4 3–15 12.89±3.8 4–16
.0±4.5 3–15 16.0±7.0 4–24
6±4.3 1–14 8.1±4.7 1.6–18
13 NA 9 NA
.9±4.8 2–15 17.8±4.2 9–28
NA NA NA NA
tor negative, RF(+) Rheumatoid Factor Positive, NA Not applicable.
Figure 2 Rheumatoid factor negative (RF-ve) Polyarticular JIA
hand deformities in a Zambian Child. Photograph showing
Juvenile Idiopathic Arthritis (JIA) hand deformities in a female
Zambian child with Rheumatoid Factor negative Polyarticular JIA.
Note the symmetrical involvement of multiple upper limb joints
(In this case the wrist and all the digital < Distal inter-phalangeal,
meta-carpophalangeal; Metatarsophalangeal; and proximal inter-
phalangeal > joints are involved with multiple deformities).
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majority of oligoarticular JIA (M 13 :F 12) had onset in
early childhood while a majority of polyarticular JIA
(F 17; M 10) had onset in late childhood. Oligoarti-
cular disease affected the lower limbs predominantly
(Figure 1). Among patients with polyarticular disease
(seronegative and seropositive), the frequency of upper
and lower limb involvement was similar and in those
with symmetrical arthritis mainly the wrists, MCPs
finger PIPs and MTP joints were affected (Figure 2).
The pattern of joint involvement at presentation was
asymmetric in those with oligoarticular disease and
symmetric in polyarticular and systemic onset disease.
The sex distribution within subgroups shows a female
predominance in RF positive polyarthritis and male
predominance in ERA subgroup. The oligoarthritis
subgroup had near sex parity and the polyarticular RF
negative group had slight female predominance.
Extra-articular clinical features in various JIA subtypes
Fever, still’s rash, eye involvement (acute/chronic uveitis
and conjunctivitis), erythrocyte sedimentation rates
(ESR) and anemia were the main noted extra-articular
clinical features. Hemoglobin (HB) level values and ESR
data records were scanty from the available data, the
overall erythrocyte sedimentation rates (ESR) were ob-
served to be variable across the various JIA subtypes
(Table 2) with an overall average of 52.3 (± 34.4 SD).
The overall average HB levels were 11.0 (±2.2 SD) with
polyarticular RF (−) showing the lowest HB levels. Ten
patients experienced inflammatory eye disease as fol-
lows: Chronic uveitis in three with oligoarticular JIA
(one blind) and 2 with ERA; Acute uveitis in one each of
ERA and polyarticular JIA; Conjunctivitis in one ERA.Figure 1 Ankle joint involvement in Oligoarticular JIA in a
Zambian Child. Photograph showing ankle joint effusion in a
Zambian male child with oligoarticular JIA. Note the asymmetrical
involvement of the lower big joints. In this case the left ankle joint
has effusion while the right is unaffected.As expected persistent fever, of at least two weeks du-
ration was observed in all systemic JIA. 37.0% of po-
lyarticular RF(−), 22.2% of polyarticular RF(+) and 16.0%
of oligoarticular JIA had episodes of none persistent
fever. Still’s rash was identified in one third Systemic
JIA subjects.
Patient clinical outcomes
The majority of patients in this series (data not shown
here) have been lost to follow up. Accordingly, it has
been impossible to assess overall clinical outcome main-
ly due to nonexistence of pediatric rheumatology care
prior to the establishment of the current pediatric rheu-
matology/immunology clinic at UTH. Clinical remission
on medication has been documented in 8 patients
(3males and 5 females) out of a total 33 JIA patients
(24.2%) who are still prospectively being followed by JC
in the established pediatric rheumatology/immunology
clinic. The average period of remission among these
eight patients, to date, is 3.4 ( ± SD 1.1) years. The ma-
jority of the documented JIA children in remission, 6
out of the 8 (75%), are with polyarticular RF(−) disease.
One of the patients has polyarticular RF(+) disease and
the other has oligoarticular JIA. It is worth noting here
that, besides facing the challenges of limited basic la-
boratory diagnostic support services such as RF, ANA,
CRP, etc., there is an erratic supply of rheumatology
drugs at UTH including basic None-steroidal Anti-
Inflammatory Drugs (NSAIDs) and even less availability
of common disease modifying anti-rheumatic drugs
(DMARDs) such as methotrexate. This limitation results
in difficulties in maintaining appropriate JIA treatment
protocols at this center and as was the case in this cli-
nical audit affects the objective assessment of long-term
patient outcome and disease prognosis.
Table 2 Extra-articular clinical features in the various JIA subtypes presenting at University Teaching Hospital, Lusaka,
Zambia
Clinical features Systemic
JIA (n = 11)
Polyarticular RF(−)
JIA (n = 27)
Polyarticular RF(+)




JIA (n = 1)
Enthesitis related
JIA (n = 5)
Overall
(n = 78)
Fever 11 (100%) 10 (37.0%) 2 (22.2%) 4 (16.0%) 1 (100%) 0 (0%) 28 (35.9%)
Still’s Rash 4 (36.4%) 2 (7.4%) 1 (11.1%) 2 (8.0%) 0 (0%) 0 (0%) 9 (11.5%)
Eye Involvement 1 (9.1%) 1 (3.7%) 1 (11.1%) 3 (12.0%) 0 (0%) 4 (80.0%) 10(12.8%)
Acute Uveitis 0 (0%) 1 (3.7%) 1 (11.1%) 0 (0%) 0 (0%) 1 (20.0%) 3 (3.8%)
Chronic Uveitis 1 (9.1%) 0 (0%) 0 (0%) 3 (12.0%) 0 (0%) 2 (40.0%) 6 (7.7%)
Conjuctivitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (20.0%) 1 (1.3%)
None 10 (90.9%) 26 (96.3%) 8 (88.9%) 22 (88.0%) 1 (100%) 1 (20.0%) 69(87.2% )
*ESR 40±29.0 59±39.2 53±2.0 44.2±22.3 ND ND 52.25±34.4
(n = 3) (n = 11) (n = 2) (n = 5) (n = 21)
HB 11.1±0.82 10.7±2.47 11.1±0.0 11.56±2.01 ND ND 11.0±2.2
(n = 3) (n = 13) (n = 2) (n = 5) (n = 23)
NB.: JIA Juvenile Idiopathic Arthritis, n number, RF (−) Rheumatoid Factor negative, RF(+) Rheumatoid Factor Positive, ND Not determined, ESR Erythrocyte
Sedimentation rate.
*It must be noted that ESR were only available in 21 out of the 78 JIA case series.
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In the past the heterogeneity in nomenclature of the dis-
ease, the lack of diagnostic tests and the differences in
diagnostic criteria may have made it difficult to under-
stand fundamental epidemiological comparisons such as
incidence, prevalence and clinical manifestations. The
current International League of Associations for Rheu-
matology (ILAR) JIA classification is contributing to a
more uniform nomenclature and nosology, and thus im-
proving comparative disease diagnosis and epidemiology
across countries and ethnic populations. For this reason
we chose to adopt the ILAR classification criteria for this
study. We realize that there is an inherent risk of error
arising from a retrospective reclassification process
(EULAR to ILAR ) for our patients in 1994–98 period
prior to the formulation and adoption of the ILARTable 3 Comparative JIA Epidemiology: developing and deve
JIA Subtypes Zambia* South Africa8
Number in the studied series 78 78
Systemic JIA (%) 14.1 7.7
Polyarticular RF (−) JIA (%) 34.6 14
Polyarticular RF (+) JIA (%) 11.5 26.9
Oligoarticular arthritis (%) 32.1 26
Psoriatic arthritis JIA (%) 1.3 1.3
Enthesitis related arthritis (%) 6.4 23
Others 0 0
Female : Male Ratio 1.2:1 1:1
Eye involvement 11.5 -
ANA Positivity - 4.48 (§3/67)
*Current Report from Zambia-Chipeta J et al.; §Note that ANA was done and availa
source references.criteria. However we are confident of the validity of this
process because of the meticulous, detailed prospective
recordings made by PN and observed by one of us
(PEM) during this era. This study covered a total period
of 9 years and has yielded 78 cases of JIA. The pre-
valence of polyarticular sero negative disease (35%) is
among the highest reported worldwide, followed by
oligoarthritis at 32%, the most common subtype de-
scribed in studies from Europe and North America [6,7]
This finding is in keeping with other studies from the
developing world (Table 3) where evidence for a lower
incidence of oligoarticular disease has been noted [7-13].
About one third of Caucasian children with oligo-
arthritis which during the first six months affects less
than four joints will continue to develop arthritis in
more joints thereafter [1]. We did identify prospectivelyloped countries
India13 Turkey14 Norway11 UK11
224 196 172 572
8 15.3 17.4 14.7
17 30.6 25.8 19.5
12 6.6 2.9 5.2
21 34.1 27.3 43.7
1 1 4.6 7.5
36 10.3 6.3 6.9
5 2.5 15.6 2
- 1:1.1 2.2:1 2.0:1
- 2 14.5 20
- 14.2 41.2 33
ble only in 67 of the 78 South African JIA case series. 8, 13,14,11 Respective data
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patients a prolonged delay in presentation to our service
and for others failure to return after initial diagnosis
(common in our setting) may have masked this dynamic
process. It is possible therefore that some children clas-
sified as polyarticular may in reality be “oligoarthritis
extended”.
The gender ratios in our study show a paucity of pre-
school girls (especially in the oligoarthritis subset), com-
pared to Caucasian studies where a FM ratio of about
5.1 is the norm. Social and cultural rather than biological
reasons may lie behind this observation. It is highly
likely that so called “milder” cases of oligoarticular dis-
ease might never reach a tertiary care facility in many
developing world settings. In the developed world
children with oligoarthritis will usually be reviewed in a
hospital setting and have access to diagnostic and thera-
peutic facilities not yet available in most of sub-Saharan
Africa. It is apparent that differences in prevalence of
oligoarthritis JIA in Africa from those reported in the in-
dustrialized west may simply be the result of a selection
bias imposed by a dearth pediatric rheumatology ser-
vices and expertise. In this context it is of interest that
in true community based studies in the developing world
the prevalence of oligo-articular disease matches or ex-
ceeds that of polyarticular disease [14-17].
Our five patients with ERA matched the pattern found
world-wide, predominantly a male disease mostly affect-
ing the lower joints with relative late childhood onset.
However in Caucasian and Indian studies the majority
of subjects with ERA are B27 positive and the prevalence
of ERA is much higher than our study and this is likely
due to the virtual absence of the B27 gene in our black
population [17,18].
An important confounding factor in the assessment of
ERA subjects is the ever present risk of HIV infection
which is strongly associated with spondyloarthropathy in
the African setting including children and juveniles.
Enthesitis is a “red flag” signal indicating the need for an
HIV test [19,20].
The extra-articular features were as expected, apart
from the poor ophthalmic outcomes in those with
chronic uveitis. As rheumatology knowledge increases
amongst doctors and other care providers in Africa,
leading to the application of standard diagnostic and
classification criteria, prevalent cases are likely to con-
tinue to resemble those reported elsewhere. Clinicians
working in parts of Africa where rheumatological ser-
vices are non-existent or rudimentary face enormous
challenges. These include a wide differential diagnostic
list and a limited arsenal of diagnostic procedures to
aid them in reaching a definitive diagnosis. Limited
training in rheumatology, and working in an environ-
ment burdened with infectious diseases, their differentialdiagnostic list is frequently limited to possible infectious
causes for rheumatological problems. Distinguishing com-
mon Rheumatic Fever from rarer JIA subtypes is one ex-
ample and unless clinicians are well-trained to recognize
the distinctive features of the two conditions, they will
have doubts about diagnosing JIA. In our setting oligo JIA
may often be attributed to trauma or thought to be infect-
ive and children with persistent or more severe joint
symptoms may be subjected to arthrotomy and prolonged
courses of antibiotics. Therefore, increasing awareness of
JIA among clinicians in Africa should lead to improve-
ments in reporting and adherence to the standard diag-
nostic criteria of the disease.
Conclusion
All categories of JIA, except the ‘undifferentiated’ (or
others), were identified in our Zambian children.
Polyarticular RF negative disease was the most common
presentation. Young females with oligoarticular disease
are underrepresented in this series compared to North
American and European series. The subgroup ERA is
uncommon and linked to a low prevalence of HLA B27
in the population. Late presentation coupled with the
absence of specialized health services are issues with
major implications for educational input and resource
acquisition.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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